Notable Upgrades: Sarepta Therapeutics (SRPT), FireEye (FEYE), GoPro, Inc. (GPRO), Micron (MU)

Analysts at Bank of America/Merrill (BAC) upgraded Sarepta Therapeutics, Inc. (SRPT) from ‘Neutral’ to ‘Buy’ in a research report issued to clients on Tuesday. The firm says it has increased confidence that Eteplirsen will be approved for treating boys with Duchenne muscular dystrophy. The target price for SRPT is raised to $21 from $19. On valuation […] View the full post at: Notable Upgrades: Sarepta Therapeutics (SRPT), FireEye (FEYE), GoPro, Inc. (GPRO), Micron (MU) Related posts: Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock